Michael Fuller
Knobbe Martens
Articles
USPTO Revises Examination Procedure after Berkheimer
USA - May 2 2018 The U.S. Patent and Trademark Office has issued new guidance to patent examiners in light of the Federal Circuit’s recent holdings in Berkheimer v. HP…
23andMe Receives First FDA Authorization for Direct-to-Consumer Cancer Risk Genetic Test
USA - March 23 2018 On March 6, 2018, 23andMe, Inc. received the first-ever FDA authorization for a direct-to-consumer genetic test that analyzes gene mutations to help…
California’s Drug Price Transparency Bill
USA - October 24 2017 On October 9, 2017, California Governor Jerry Brown signed the new drug price transparency bill SB 17. The new law requires pharmaceutical…
The Role of Analogies in the Alice Analysis
USA - September 8 2017 Courts increasingly rely on analogies to show that claims are not directed to patent-eligible subject matter under 35 U.S.C. § 101. For example…
Litigation Misconduct Helps Render a Patent Unenforceable
USA - August 22 2017 In March 2014, Regeneron Pharmaceuticals, Inc. sued Merus B.V. for allegedly infringing U.S. Patent No. 8,502,018 ("the '018 Patent"). The '018 Patent…
